Global HIV Vaccine Enterprise
MISSION: Unite stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.
Under the newly launched Global HIV Vaccine Enterprise Strategic Plan (2018-2023), the International AIDS Society (IAS) will be working in close collaboration with major HIV vaccine stakeholders to ensure that the field is sustained by a robust portfolio of vaccine candidates in clinical trials, is prepared for making a successful vaccine available to all and is propelled by increased and diversified funding for research and development.
The renewed five-year strategy aims to address major challenges confronting the HIV vaccine landscape by advancing three pivotal commitments:
- Propelling the vaccine pipeline by strengthening strategies to align, amplify and accelerate development of candidate vaccines
- Preparing for success by tackling priorities essential to clarifying the roadmap for future access to a vaccine
- Expanding resources and engagement by enlisting a diverse community of partners to support and contribute to the field.
This is a critical moment for the HIV vaccine development field, characterized by renewed momentum and unprecedented promise. This strategic plan advances a shared vision to develop a safe and effective HIV vaccine available to the world.
Established more than a decade ago, the Global HIV Vaccine Enterprise – known as the Enterprise – has championed a commitment to accelerating HIV vaccine development by serving as a neutral convener that promotes coordination, collaboration, knowledge sharing and mobilization of resources. As the Enterprise transitions to the International AIDS Society, the IAS has an opportunity to reaffirm the Enterprise’s mission in the context of a transformed landscape and to engage new stakeholders and funders in a diversified, resilient and truly global alliance.